

Supporting Information

Simple Unprecedented Conversion of Phosphine Oxides and Sulfides to Phosphine Boranes using Sodium Borohydride

Kamalraj V. Rajendran and Declan G. Gilheany*

Centre for Synthesis and Chemical Biology, School of Chemistry and Chemical Biology, University College Dublin, Belfield, Dublin 4, Ireland

Contents

Table of contents.....	01
General Experimental.....	02
Synthesis of phosphine oxides and sulfides.....	05
General Procedure for Reduction of Achiral Racemic Tertiary and Secondary phosphine oxide and sulfides using oxalyl chloride and sodium borohydride	10
Table A. Reduction of achiral and racemic tertiary phosphine oxides and sulfides.	10
Table B. Reduction of racemic secondary phosphine oxides and sulfide.....	13
Reduction of Enantioenriched phosphine oxide (Table C.).....	22
General Procedure for the Stereospecific Conversion of Enantioenriched Phosphine oxide to phosphine borane	23
Table D. Stereospecific reduction/boronation of enantioenriched phosphine oxide.	23
Determination of absolute configurations of phosphine oxide and borane	26
NMR spectra and HPLC traces of phosphine boranes.....	29
References.....	91

General Experimental

Melting points were determined on a Reichert Thermovar melting point apparatus and are uncorrected. Elemental analyses were carried out by the Microanalytical Laboratory, University College Dublin. IR spectra were obtained on a Varian 3100 FTIR Excalibur series spectrometer. Routine electrospray mass spectra were obtained on a Micromass Quattro spectrometer. High-resolution mass spectra were run on a Waters Micromass GCT system either in (CI) chemical ionization or (EI) electron ionization mode, also at UCD. The NMR spectra were recorded at 25 °C on Varian VNMRS 300, 400, and 500 MHz spectrometers. ¹³C NMR spectra (³¹P decoupled) were recorded on a VNMRS 600 MHz spectrometer. All NMR samples of potentially air-sensitive compounds were made up under nitrogen by syringing a small amount of a solution into an NMR tube contained in a long Schlenk tube that was charged with an atmosphere of nitrogen, and then adding dry CDCl₃ to dissolve the compound. The NMR tube was then taken out using tweezers. CDCl₃ was purchased from Aldrich, and dried by adding to a Young's flask containing activated molecular sieves (4 Å) under an atmosphere of nitrogen. It was then stored under nitrogen in the Young's flask over the molecular sieves.

High-performance liquid chromatography was performed on a Agilent Technologies 1200 series equipped with a 6 column switching device. HPLC grade solvents, purchased from Aldrich and Lennox Supplies Ireland, were used as supplied. All samples were filtered through an Acrodisc CR 13 mm syringe filter with 0.2 µm PTFE prior to injection.

Unless otherwise stated all reactions were carried out under N₂ atmosphere in dry glassware using Schlenk-line techniques and all glassware was flame dried prior to use. Air and moisture sensitive liquids and solutions were transferred *via* syringe. All commercially available solvents were used as supplied unless otherwise stated. All "dry" solvents were dried and distilled by standard procedures¹ or were processed through a Grubbs type still, supplied by Innovative Technology Inc. Pure Solv-400-3-MD solvent purification system. Oxygen free nitrogen was obtained from BOC gases and was used without further drying. Thin layer chromatography (TLC) was performed on Merck pre-coated Kieselgel 60F₂₅₄ aluminium plates with realization by UV irradiation. Flash column chromatography was performed on Merck silica 9385, particle size 0.040-0.063 mm. Magnesium turnings for Grignard reactions were heated to 180 °C for at least 24 hours prior to use. Further activation was achieved by heating and stirring vigorously under vacuum for approximately 10 minutes immediately prior to reaction. 4 Å Molecular sieves were kept stored in an oven at 180 °C at all times. Prior to use

sieves were heated to ~300 °C, using a heat gun, for 2 minutes while under vacuum. They were allowed to cool to room temperature and this procedure was then repeated.


Oxalyl chloride, triphenylphosphine oxide, triphenylphosphine sulfide, tributylphosphine oxide, BINAP, Meerwein's salts, methyl triflate, methyl tosylate, methyl iodide, sulfuryl chloride, methane sulfuryl chloride, thionyl chloride, NaBH₄ and other reagents were purchased from Sigma-Aldrich, Fluka or Merck & Co., Inc. (±)-1,2-ethandiylbis(*o*-anisylphenyl)phenylphosphine oxide and (±)-1,2-ethandiylbis(*o*-tolylphenyl)phenylphosphine oxide were gifted by Celtic Catalysts Ltd. BINAPO was made from BINAP by oxidation with hydrogen peroxide.²

Enantioenriched methylphenyl-*o*-tolylphosphine oxide 93% ee (*S*), *o*-Anisylmethylphenylphosphine oxide 95 % ee (*R*) were gifted by Celtic Catalysts Ltd. (2-Biphenyl)methylphenylphosphine oxide 81 % ee (*S*), *tert*-Butylmethylphenylphosphine oxide 46 % ee (*S*); 53 % ee (*R*), methylphenyl(mesityl)phosphine oxide 44 % ee (*R*) were synthesised by asymmetric Appel reaction.^{2,3}


A number of the required phosphines, phosphine oxides, and phosphine sulfides were synthesised previously by us as follows.

Compound	Reference
Methylphenyl- <i>o</i> -tolylphosphine oxide	2
<i>o</i> -Anisylmethylphenylphosphine oxide	2
Methylphenyl-(2-trifluoromethyl)phenylphosphine oxide	3
(2-Biphenyl)methylphenylphosphine oxide	3
(4-Fluoro-2-methylphenyl)methylphenylphosphine oxide:	3
(2,4-Dimethylphenyl)methylphenylphosphine oxide	3
Methylphenyl(2- <i>i</i> -propylphenyl)phosphine oxide:	2
(±)-Methyl-(1-naphthyl)phenylphosphine oxide	3


<i>tert</i> -Butylmethylphenylphosphine oxide	2
Cyclohexylmethylphenylphosphine oxide	Made by the same method. Data given below



(±)-Cyclohexylmethylphenylphosphine oxide: From Phosphine (2 g, 9.7 mmol), in a yield of (1.8 g, 84%) ^1H NMR (CDCl_3 , 300 MHz): $\delta = 7.71$ -7.46 (m, 5H, Ar) 1.68 (d, $^2J_{\text{PH}} = 12.4$ Hz, 3H, PCH_3), 1.69-1.16 (m, 11H, *c*-Hexyl) ppm. ^{31}P NMR (CDCl_3 , 300 MHz): $\delta = 40.6$ ppm (Lit.⁴ -33.1 ppm).




***P*-phenyldibenzophosphole oxide:** From *P*-phenyl dibenzophosphole⁵ (2 g, 7.7 mmol), by oxidation with hydrogen peroxide² gave *P*-phenyldibenzophosphole oxide (1.82 g, 86%) ^1H NMR (CDCl_3 , 300 MHz): $\delta = 7.80$ -7.29 (m, 13H, Ar) ppm. ^{31}P NMR (CDCl_3 , 300 MHz): $\delta = 33.5$ ppm (lit.⁵ 33.8)




Methylphenyl(mesityl)phosphine oxide⁶: From methylphenyl(mesityl)phosphine⁷ (1g, 4.1 mmol) by oxidation with hydrogen peroxide gave methylphenyl(mesityl)phosphine oxide (0.86 g, 81%); ^1H NMR (CDCl_3 , 300 MHz): $\delta = 7.64$ -7.46 (m, 2H, Ar), 7.50-7.38 (m, 3H, Ar), 6.90-6.89 (m, 2H, Ar), 2.41 (s, 6H, *o*-Me), 2.30 (s, 3H, *p*-Me), 1.21 (d, $^2J_{\text{PH}} = 6.0$ Hz, 3H, PCH_3); ^{31}P NMR (CDCl_3 , 300 MHz): $\delta = 34.6$ ppm.

Synthesis of Required Secondary Phosphine oxides




Exemplar: Synthesis of *o*-tolylphenylphosphine oxide:⁸ A dry 100 mL two-necked round bottom flask fitted with reflux condenser, nitrogen inlet and outlet and septum was charged with magnesium turnings (0.5 g, 18.7 mmol, 1.1 equiv). 2-Bromotoluene (3.0 g, 17 mmol, 1 equiv) was dissolved in THF (10 mL), and approx. 2 mL of this solution was added to the flask *via* syringe. The mixture was heated to reflux with vigorous stirring until the reaction initiated, at which point the remainder of the solution was added over approximately 30 minutes, also *via* syringe. After this time the reaction was refluxed for a further 2 hours. The reaction was allowed to cool to room temperature and, it was then transferred through a syringe into a pressure-equalized dropping funnel attached to a flame dried and degassed 100 mL round bottom flask, which had been charged previously with dichlorophenylphosphine (3.0 g, 17 mmol, 1 equiv) and anhydrous THF (10 mL). This solution was cooled to -78 °C using dry ice-acetone mixture and the Grignard solution was added dropwise over 1 hour. The flask was allowed to warm to room temperature and was then stirred for an hour. A 10% aqueous solution of H₂SO₄ (100 mL) was added dropwise to the reaction mixture at 0 °C and the reaction was allowed stirred for an hour. The solvent was removed *in vacuo*, and extracted with dichloromethane (3 ×100 mL), which had been stored over anhydrous magnesium sulfate for 30 min under a nitrogen atmosphere. The extracts were filtered through a sintered funnel under nitrogen, the solvent removed *in vacuo*, phosphine oxide was isolated as colourless oil.




(±)-*o*-tolylphenylphosphine oxide: (3.35 g, 88 %) ¹H NMR (CDCl₃, 300 MHz): δ = 8.13 (d, *J*_{HP} = 483.8 Hz, 1H), 7.75-7.21 (m, 9H, Ar), 2.35 (s, 3H, ArCH₃). ¹³C NMR {¹H, ³¹P} (CDCl₃, 151 MHz): δ = 141.4, 132.8, 132.3, 132.2, 131.42, 131.41, 130.8, 129.5, 128.9, 126.0, 20.2. ³¹P NMR (CDCl₃, 121 MHz): δ = 21.6 (lit⁸ 21.9) ppm. HRMS (CI) Calc. 216.0704;

found: 216.0701. HPLC (CHIRALCEL[®] IA column, 90:10 Heptane - EtOH, 1 mL/min R_t: 18.4 min, 19.9 min.





(±)-*tert*-Butylphenylphosphine oxide: From PhPCl₂ (3.0 g, 17 mmol, 1 equiv) and ^tBuMgBr (17 mL 1.0 M in THF 1 equiv) by the procedure above gave (±)-*tert*-Butylphenylphosphine oxide (2.65 g, 85 %) ¹H NMR (CDCl₃, 300 MHz): δ = 7.68-7.38 (m, 5H, Ar), 7.08 (d, *J*_{HP} = 458.9 Hz, 1H), 1.15(d, *J*_{HP}= 16.5 Hz, 9H) ¹³C NMR {¹H, ³¹P} (CDCl₃, 151 MHz): δ = 132.6, 130.9, 128.4, 127.7, 23.7, 23.6. ³¹P NMR (CDCl₃, 121 MHz): δ =47.4 (lit⁸ 47.6) ppm. HRMS (CI) Calc. 182.0861; found: 182.0857. HPLC (CHIRALCEL[®] IA column, 90:10 Heptane - EtOH, 1 mL/min R_t: 18.4 min, 19.9 min.




(±)-*tert*-Butylphenylphosphine sulfide: From PhPCl₂ (3.0 g, 17 mmol, 1 equiv), ^tBuMgBr (17 mL 1.0 M in THF 1 equiv), LiAlH₄(8.5 mL 2.0 M in THF 1 equiv.) and sulphur (0.65 g, 1.2 equiv, 20.4 mmol) by the procedure above gave (±)-*tert*-Butylphenylphosphine sulphide as solid (2.64 g, 78%) ¹H NMR (CDCl₃, 300 MHz): δ = 7.48-7.18 (m, 5H, Ar), 6.83 (d, *J*_{HP} = 458.9 Hz, 1H), 0.9 (d, *J*_{HP}= 16.5 Hz, 9H) ³¹P NMR (CDCl₃, 121 MHz): δ =54.0 (lit⁹ 54.0)

Synthesis of methylphenylphosphine oxide⁴




Synthesis of dimethylphenylphosphonite: A 500 mL 2 necked round bottom flask equipped with a pressure equalised dropping funnel attached to a Schlenk line was charged with anhydrous pyridine (80 mL, 0.9 mol), dichlorophenylphosphine (84 g, 0.46 mol) and degassed pentane (250 mL).


The stirred solution was cooled to 0 °C and anhydrous methanol (38 mL, 0.93 mol) in degassed pentane (25 mL) was added over a period of 2 hours. The pyridine hydrochloride salt was filtered off under N₂ and the filtrate was concentrated under reduced pressure. The crude grainy colourless liquid product was carried onto the next step without further purification. (38 g, 47 %) ³¹P NMR (CDCl₃, 121 MHz): δ =165.09 ppm.



Synthesis of methyl-methylphenylphosphinate : A 3-neck 250 mL round bottom flask was fitted with a thermometer and two condensers, one of which was connected to a pressure equalised dropping funnel which in turn was connected to a Schlenk lin via a stop-cock adaptor. The flask was charged with a small amount of dimethylphenylphosphonite (3 mL) and a few drops of methyl iodide. The orange mixture was stirred and warmed carefully under a N₂ atmosphere until a very vigorous exothermic reaction began. The phosphonite (35 g, 0.21 mol) was added at a rate sufficient to keep the temperature at roughly 70 °C. It was necessary to periodically add small amount of methyl iodide to maintain a constant reaction. After completer addition the red mixture was stirred at room temperature overnight. Distillation under reduced pressure (98°C @ 0.4 mm Hg) yielded a colourless oil (27.2 g 78%). ³¹P NMR (CDCl₃, 121 MHz): δ =48.7 ppm.





Synthesis of methylphenylphosphine: To a stirred solution of LiAlH₄ (1 M soln. In THF 50 mL, 50 mmol) in dry THF (25 mL) at -78 °C was added a solution of a methylphenylphosphinate (5.0 g, 29.4 mmol) in dry THF (75 mL) over 1 hour. After warming to room temperature the solution was then refluxed for 4 hours. After removal of THF under reduced pressure, degassed H₂O (20 mL) was added very slowly, followed by degassed aqueous NaOH (20% 20 mL) and finally degassed H₂O (20 mL). The product was extracted into degassed DCM (2 x 100 mL), dried over MgSO₄ and the solvent removed under reduced pressure. ³¹P NMR (CDCl₃, 121 MHz): δ = -76.4 ppm.




methylphenylphosphine oxide: The phosphine from previous reaction was opened to air and left for 3 days for complete conversion to oxide. (2.9 g 70 %) ¹H NMR (CDCl₃, 300 MHz): δ = 7.80-7.42 (m, 5H, Ar), 7.64 (d, J_{HP} = 484.4 Hz, 1H), 1.81 (d, J_{HP}= 11 Hz, 3H) ³¹P NMR (CDCl₃, 121 MHz): δ =21.2 (lit⁸ 20.3).


Synthesis of Required Phosphine Sulfides




Exemplar Synthesis of (±)-*o*-anisylmethylphenylphosphine sulfide: To a stirred solution of phosphine (0.5 g, 2.1 mmol, 1 equiv) in DCM (30 mL, degassed) at 0 °C (ice bath) sulphur (74 mg, 1.2 equiv) was added through powder funnel. After the addition was complete the suspension was stirred for 2 hrs. Excess sulphur was filtered off and the solvent was removed in *vacuo* to yield light yellow solid. (0.5 g 90%) ¹H NMR (CDCl₃, 300 MHz): δ = 8.20-8.13 (m, 1H, Ar), 7.68-7.63 (m, 2H, Ar), 7.45-7.19 (m, 4H, Ar), 7.07-7.04 (m, 1H, Ar), 6.81-6.78 (m, 1H, Ar), 3.59 (s, 3H, OCH₃), 2.29 (d, ²J_{PH} = 14.4 Hz, 3H, CH₃); ³¹P NMR (CDCl₃, 121 MHz): δ = 35.2 (lit¹⁰ 35.9) ppm.




(±)-*o*-tolylmethylphenylphosphine sulfide: From phosphine² (2 g, 9.3 mmol), in a yield of (1.9 g, 82%) ¹H NMR (CDCl₃, 300 MHz): δ = 8.48-8.40 (m, 3H, Ar), 8.32-8.24 (m, 4H, Ar), 7.92-7.521 (m, 2H, Ar), 2.75 (s, 3H, ArCH₃), 2.32 (d, ²J_{PH} = 14.1 Hz, 3H, CH₃) ppm. ³¹P NMR (CDCl₃, 121 MHz): δ = 34.7 (lit¹¹ 34.4) ppm.



(±)-(2-Biphenyl)methylphenylphosphine sulfide : From phosphine³ (2 g, 7.2 mmol), in a yield of (1.8 g, 81%) ¹H NMR (CDCl₃, 300 MHz) : δ = 8.60-7.24 (m, 14H, Ar), 2.29 (d, ²J_{PH} = 14.1 Hz, 3H, CH₃) ppm. ³¹P NMR (CDCl₃, 121 MHz): δ = 37.2 ppm. ¹³C NMR {¹H,³¹P} (CDCl₃, 151 MHz): δ = 136.5, 132.8, 132.2, 131.5, 130.4, 129.7, 129.3, 128.8, 127.9, 127.7, 127.3, 126.3, 125.3, 121.1, 23.2 ppm. IR: ν̃ = 3185, 2468, 1621, 1342, 1292, 585 (P=S) cm⁻¹. HRMS (EI): C₁₉ H₁₇ PS Calculated: 308.0788 Found: 308.0781.



(±)-Methylphenyl(2-trifluoromethylphenyl)phosphine sulfide : From phosphine³ (1 g, 5.5 mmol), in a yield of (0.55 g, 87%) ¹H NMR (CDCl₃, 300 MHz): δ = 8.01-7.42 (m, 9H, Ar), 2.4 (d, ²J_{PH} = 12.2, Hz, 3H, PCH₃) ppm. ³¹P NMR (CDCl₃, 121 MHz): δ = 40.6 ppm. ¹³C NMR {¹H, ³¹P} (CDCl₃, 151 MHz): δ = 136.9, 135.4, 133.1, 132.9, 132.7, 131.8, 131.4, 130.0, 129.4, 127.4, 123.5 (q, J = 273.2 Hz), 17.6 ppm. IR: ν̄ = 3213, 1649, 1521, 1474, 1232, 595 (P=S) cm⁻¹. HRMS (EI): C₁₄ H₁₂ F₃PS Calculated: 300.0349 Found: 300.0342.






(±)-Methylphenyl(2-*i*-propylphenyl)phosphine sulfide : From phosphine² 2 g, 8.2 mmol), in a yield of (1.81 g, 80%) ¹H NMR (CDCl₃, 300 MHz): δ = 7.62-7.12 (m, 9H, Ar) 3.24 (quintet, J = 6.7 Hz, 1H, CH), 2.21 (d, ²J_{PH} = 14.0 Hz, 3H, PCH₃), 1.34 (d, J = 6.8 Hz 3H, *i*-Pr-Me), 0.92 ³¹P NMR (CDCl₃, 121 MHz): δ = 37.3 ppm. ¹³C NMR {¹H, ³¹P} (CDCl₃, 151 MHz): δ = 154.3, 136.2, 134.9, 132.9, 131.4, 130.2, 129.2, 128.3, 127.4, 125.5, 32.5, 23.4, 17.6 ppm. IR: ν̄ = 3385, 2868, 1521, 1592, 1474, 1364, 580 (P=S) cm⁻¹. HRMS (EI): C₁₆ H₁₉ PS Calculated: 274.0945 Found: 274.0939.












General Procedure for Reduction of Achiral Racemic Tertiary and Secondary phosphine oxide and sulfides using oxalyl chloride and sodium borohydride.





To a stirred solution of phosphine oxide/sulfide (1.0 mmol) in toluene (2 mL) was added oxalyl chloride (1.0 mmol) dissolved in toluene (2 mL) dropwise at room temperature under a nitrogen atmosphere. At this point ^{31}P -NMR of the reaction mixture shows full conversion to chlorophosphosonium salt (CPS). After 30 min, sodium borohydride (2.1 mmol) dissolved in diglyme (~3 mL) was added dropwise to the reaction mixture. This mixture was stirred for 1 h, where ^{31}P shows full completion of CPS to phosphine borane. The reaction mixture was washed with deionised water (5 mL) and the isolated organic layer was dried over anhydrous MgSO_4 . The drying agent was removed by filtration, and the solvent was removed *in vacuo* to give colourless oil, which was eluted through a silica plug with 50:50 cyclohexane/ethylacetate. Solvent removal *in vacuo* yielded the pure phosphine borane.

Table A. Reduction of achiral and racemic tertiary phosphine oxides and sulfides.




Entry	Starting material	^{31}P -NMR Chemical Shift (ppm)		
		PX ^a	CPS ^b	PB ^c
1		X = O 25.2	64.4 ²³	21.5
		X = S 42.1		
2		X = O 32.5	71.0	10.2
		X = S 34.7		




3		X= O 28.5	70.5	8.4
		X= S 35.2		
4		32.4	73.8	18.4
5		34.8	72.1	18.8
6		23.0	62.6	21.4
7		33.5	57.6	25.0
8		X= O 26.9	67.1	13.3
		X= S 37.2		
9		X= O 32.2	70.8	9.1
		X = S 37.3		
10		X =O 31.6	66.8	18.4
		X = S 40.6		
11		33.1	70.2	13.3
12		31.7	71.0	10.5 ^d
13		31.0	70.4	10.2 ^d

14		34.6	72.0	11.6
15		40.6	91.9	17.1
16		47.0	100.9	25.8
17		56.2	105.1	14.1


^a : PX: phosphine oxide or sulfide; ^b : CPS: shift assigned as chlorophosphonium salt; ^c : PB phosphine borane, isolated yield > 85%. No other material was apparent in the ³¹P NMR of the crude reaction mixture. Unless otherwise noted, these are known compounds - literature references given in ESI; ^d : this work.

Table B. Reduction of racemic secondary phosphine oxides and sulfide.




Entry	Starting material	³¹ P-NMR Chemical Shift (ppm)		
		PX ^a	CPS ^b	PB ^c
1		21.6	78.4	-6.3
2		21.2	100.9	-13.5
2		X = O 47.4	107.7	31.0
		X = S 54.0		

^a PX: phosphine oxide or sulfide ; ^b CPS: shift assigned as chlorophosphonium salt; ^c PB: phosphine borane, isolated yield > 85%. No other material was apparent in the ³¹P nmr of the crude reaction mixture. These are known compounds - literature references given in SI.




Triphenylphosphine borane : From triphenylphosphine oxide (0.27 g, 1.0 mmol, 1 equiv) treated with oxalyl chloride (0.1 mL, 1.0 mmol, 1 equiv.) followed by the treatment with NaBH₄ in diglyme (3.4 mL, 0.6 M, 2.1 mmol, 2.1 equiv) gave triphenylphosphine borane. (0.24 g, 88%) ¹H NMR (CDCl₃, 300 MHz): δ = 7.61–7.40 (m, 15H, Ph-H), 1.74–0.83 (br, 3H, BH₃) ppm. ³¹P NMR (CDCl₃, 121 MHz): δ = 21.5 (lit.¹²) 20.6 ppm.

Triphenylphosphine borane : From triphenylphosphine sulfide (0.29 g, 1.0 mmol, 1 equiv) treated with oxalyl chloride (0.1 mL, 1.0 mmol, 1 equiv.) followed by the treatment with NaBH₄ in diglyme (3.4 mL, 0.6 M, 2.1 mmol, 2.1 equiv) gave triphenylphosphine borane. (0.25 g, 92%) ³¹P NMR (CDCl₃, 121 MHz): δ = 21.5 (lit.¹² above) 20.6 ppm.



Methylphenyl(o-tolyl)phosphine borane : From methylphenyl(o-tolyl)phosphine oxide (0.23 g, 1.0 mmol, 1 equiv) treated with oxalyl chloride (0.1 mL, 1.0 mmol, 1 equiv.) followed by the treatment with NaBH₄ in diglyme (3.4 mL, 0.6 M, 2.1 mmol, 2.1 equiv) gave methylphenyl(o-tolyl)phosphine borane (0.20 g, 87%) ¹H NMR (CDCl₃, 300 MHz): δ = 7.72–7.14 (m, 9 H, Ar), 2.17 (s, 3 H, ArCH₃), 1.82 (d, ²J_{PH} = 9.8 Hz, 3 H, CH₃) 1.61–0.72 (br, 3H, BH₃) ppm. ³¹P NMR (CDCl₃, 121 MHz): δ = 10.2 (lit¹³ 10.9) ppm


Methylphenyl(o-tolyl)phosphine borane : From methylphenyl(o-tolyl)phosphine sulfide (0.24 g, 1.0 mmol, 1 equiv) treated with oxalyl chloride (0.1 mL, 1.0 mmol, 1 equiv.) followed by the treatment with NaBH₄ in diglyme (3.4 mL, 0.6 M, 2.1 mmol, 2.1 equiv) gave methylphenyl(o-tolyl)phosphine borane (0.21 g, 91%) ³¹P NMR (CDCl₃, 121 MHz): δ = 10.5 (lit¹³ 10.9) ppm



Methylphenyl(o-anisyl)phosphine borane : From methylphenyl(o-anisyl)phosphine oxide (0.24 g, 1.0 mmol, 1 equiv) treated with oxalyl chloride (0.1 mL, 1.0 mmol, 1 equiv.) followed by the treatment with NaBH₄ in diglyme (3.4 mL, 0.6 M, 2.1 mmol, 2.1 equiv) gave methylphenyl(o-anisyl)phosphine borane. (0.22 g, 91%) ¹H NMR


(CDCl₃, 300 MHz): δ = 7.90–6.77 (m, 9 H, Ar), 3.68 (s, 3 H, Ar-OCH₃), 1.94 (d, $^2J_{\text{PH}} = 10.2$ Hz, 3H, CH₃) 1.43–0.50 (br, 3H, BH₃) ppm ^{31}P NMR (CDCl₃, 121 MHz): δ = 8.4 (lit¹⁴ 9.2) ppm.

Methylphenyl(*o*-anisyl)phosphine borane : From methylphenyl(*o*-anisyl)phosphine sulfide (0.26 g, 1.0 mmol, 1 equiv) treated with oxalyl chloride (0.1 mL, 1.0 mmol, 1 equiv.) followed by the treatment with NaBH₄ in diglyme (3.4 mL, 0.6 M, 2.1 mmol, 2.1 equiv) gave methylphenyl(*o*-anisyl)phosphine borane. (0.21 g, 87%) ^{31}P NMR (CDCl₃, 121 MHz): δ = 8.7 (lit¹⁴ 9.2) ppm



(±)-1,2-Ethandiylbis[(*o*-anisylphenyl)phenylphosphine borane:


From 1,2-ethandiylbis[(*o*-anisylphenyl)phenylphosphine oxide (0.49 g, 1.0 mmol, 1 equiv) treated with oxalyl chloride (0.2 mL, 2.0 mmol, 2 equiv.) followed by the treatment with NaBH₄ in diglyme (6.9 mL, 0.6 M, 4.2 mmol, 4.2 equiv) gave 1,2-ethandiylbis[(*o*-anisylphenyl)phenylphosphine borane (0.42 g, 87%) ^1H NMR (CDCl₃, 300 MHz): δ = 7.90-7.83 (m, 2H, Ar), 7.69-7.64 (m, 4H, Ar), 7.49-7.36 (m, 8H, Ar), 7.05-7.00 (m, 2H, Ar), 6.83-6.80 (m, 2H, Ar), 3.62 (s, 6H, OCH₃), 1.87 (m, 4H, P-CH₂), 1.22–0.90 (br, 6H, BH₃) ppm. ^{31}P NMR (CDCl₃, 300 MHz): δ = 18.5 ppm (lit¹⁵ 18.8 ppm).



(±)-1,2-Ethandiylbis[(*o*-tolylphenyl)phenylphosphine borane :


From 1,2-ethandiylbis[(*o*-tolylphenyl)phenylphosphine (0.46 g, 1.0 mmol, 1 equiv) treated with oxalyl chloride (0.2 mL, 2.0 mmol, 2 equiv.) followed by the treatment with NaBH₄ in diglyme (6.9 mL, 0.6 M, 4.2 mmol, 4.2 equiv) gave 1,2-ethandiylbis[(*o*-tolylphenyl)phenylphosphine borane. (0.43 g, 88%) ^1H NMR (CDCl₃, 300 MHz): δ = 7.66-7.60 (m, 2H, Ar), 7.52-7.37 (m, 8H, Ar), 7.30-7.26 (m, 2H, Ar), 7.20-7.18 (m, 6H, Ar), 2.14 (s, 6H, CH₃), 2.48 (m, 4H, P-CH₂), 1.26–0.88 (br, 6H, BH₃) ppm. ^{31}P NMR (CDCl₃, 300 MHz): δ = 18.5 ppm (lit.¹³ 19.1 ppm)

1,1'-Binaphthalene-2,2'-diyl)bis(diphenylphosphineborane): From (1,1'-Binaphthalene-2,2'-diyl)bis




(diphenylphosphine oxide) (0.33 g, 0.5 mmol, 1 equiv) treated with oxalyl chloride (0.2 mL, 1.0 mmol, 2 equiv.) followed by the treatment with NaBH₄ in diglyme (6.9 mL, 0.6 M, 2.1 mmol, 4.2 equiv) gave 1,1'-Binaphthalene-2,2'-diyl)bis(diphenylphosphine borane) (0.29 g, 87%)

¹H NMR (CDCl₃, 300 MHz): δ = 7.94 (d, *J* = 8.5 Hz, 2H), 7.84 (d, *J* = 8.2 Hz, 2H), 7.82 (dd, *J* = 8.5 Hz, *J* = 2.2 Hz, 2H), 7.74–7.52 (m, 20H), 7.41 (m, 2H), 7.39 (m, 2H), 7.36 (d, *J* = 8.5 Hz, 2H). 1.69–0.72 (br, 6H, BH₃) ³¹P NMR (CDCl₃, 300 MHz): δ = 23.0 (lit.¹⁶ 23.0) ppm.



P-Phenyldibenzophosphole borane: From *P*-phenyldibenzophosphole oxide (0.28 g, 1.0 mmol, 1 equiv) treated with oxalyl chloride (0.1 mL, 1.0 mmol, 1 equiv.) followed by the treatment with NaBH₄ in diglyme (3.4 mL, 0.6 M, 2.1 mmol, 2.1 equiv) gave *P*-phenyldibenzophosphole borane. (0.25 g, 93%); ¹H NMR (CDCl₃, 300 MHz): δ = 7.90–7.29 (m, 13H, Ar), 0.90–1.43 (b, m, 3H, BH₃) ppm. ³¹P NMR (CDCl₃, 121 MHz): δ = 25.0 ppm. ¹³C NMR {¹H, ³¹P} (CDCl₃, 151 MHz): δ = 142.3, 132.7, 132.1, 131.0, 130.9, 129.4, 127.9, 127.1, 126.6, 120.3 ppm. ¹¹B NMR (128 MHz, CDCl₃) δ = -39.6 ppm. IR (KBr, cm⁻¹) ν: 3053, 2395 (BH₃), 1636, 1593, 1438, 1294, 1164, 1027, 766. HRMS (M - BH₃ + H)⁺ C₁₈H₁₄P Calculated: 261.0833 Found: 261.0828.




(±)-(2-Biphenyl)methylphenylphosphine borane : From (±)-(2-Biphenyl)methylphenylphosphine oxide (0.29 g, 1.0 mmol, 1 equiv) treated with oxalyl chloride (0.1 mL, 1.0 mmol, 1 equiv.) followed by the treatment with NaBH₄ in diglyme (3.4 mL, 0.6 M, 2.1 mmol, 2.1 equiv) gave (2-Biphenyl)methylphenylphosphine borane. (0.26 g, 89%) ¹H

NMR (CDCl₃, 300 MHz): δ = 7.89–7.82 (m, 5H, Ar), 7.70–7.19 (m, 9 H, Ar), 1.41 (d, ²*J*_{PH} = 10.1 Hz, 3 H, CH₃), 1.56–0.73 (br, 3H, BH₃) ppm. ³¹P NMR (CDCl₃, 121 MHz): δ = 13.3 (lit.¹⁷ 14.4) ppm.


(±)-(2-Biphenyl)methylphenylphosphine borane : From (±)-(2-Biphenyl)methylphenylphosphine sulfide (0.31 g, 1.0 mmol, 1 equiv) treated with oxalyl chloride (0.1 mL, 1.0 mmol, 1 equiv.)

followed by the treatment with NaBH₄ in diglyme (3.4 mL, 0.6 M, 2.1 mmol, 2.1 equiv) gave (2-Biphenyl)methylphenylphosphine borane. (0.24 g, 85%) . ³¹P NMR (CDCl₃, 121 MHz): δ = 13.8 (lit.¹⁷ 14.4) ppm.



(±)-Methylphenyl(2-*iso*-propylphenyl)phosphine borane: From methylphenyl -(2-*iso*-propylphenyl)phosphine oxide (0.26 g, 1.0 mmol, 1 equiv) treated with oxalyl chloride (0.1 mL, 1.0 mmol, 1 equiv.) followed by the treatment with NaBH₄ in diglyme (3.4 mL, 0.6 M, 2.1 mmol, 2.1 equiv) gave methylphenyl(2-*iso*-propylphenyl)phosphine borane. (0.24 g, 92%) ¹H NMR (CDCl₃, 300 MHz): δ = 7.67-7.26 (m, 9H, Ar) 3.18 (quintet, *J* = 6.7 Hz, 1H, CH₃), 1.86 (d, ²*J*_{PH} = 10.0 Hz, 3H, PCH₃), 1.08 (d, *J* = 6.8 Hz 3H, *i*-Pr-Me), 0.73 (d, *J* = 7.4 Hz, 3H, *i*-Pr-Me); 1.62–0.51 (br, 3H, BH₃) ppm. ³¹P NMR (CDCl₃, 300 MHz) : δ = 9.0 ppm (lit¹³ 9.7ppm).


(±)-Methylphenyl(2-*iso*-propylphenyl)phosphine borane: From methylphenyl -(2-*iso*-propylphenyl)phosphine sulfide (0.27 g, 1.0 mmol, 1 equiv) treated with oxalyl chloride (0.1 mL, 1.0 mmol, 1 equiv.) followed by the treatment with NaBH₄ in diglyme (3.4 mL, 0.6 M, 2.1 mmol, 2.1 equiv) gave methylphenyl(2-*iso*-propylphenyl)phosphine borane. (0.22 g, 86%) ³¹P NMR (CDCl₃, 300 MHz) : δ = 9.3 ppm (lit¹³ 9.7ppm).




(±)-Methylphenyl (2-trifluoromethylphenyl)phosphine borane¹⁸ : From methylphenyl (2-trifluoromethylphenyl)phosphine oxide (0.28 g, 1.0 mmol, 1 equiv) treated with oxalyl chloride (0.1 mL, 1.0 mmol, 1 equiv.) followed by the treatment with NaBH₄ in diglyme (3.4 mL, 0.6 M, 2.1 mmol, 2.1 equiv) gave methylphenyl (2-trifluoromethylphenyl)phosphine borane. (0.26 g, 92%) ¹H NMR (CDCl₃, 300 MHz): δ = 7.70-7.02 (m, 9H, Ar), 1.91 (d, ²*J*_{PH} = 9.9 Hz, 3H, PCH₃), 0.65-1.53 (br, m, 3H) ppm. ³¹P NMR (CDCl₃, 121 MHz): δ = 18.3. (lit¹⁸ 18.7)

(±)-Methylphenyl (2-trifluoromethylphenyl)phosphine borane : From methylphenyl (2-trifluoromethylphenyl)phosphine sulfide (0.30 g, 1.0 mmol, 1 equiv) treated with oxalyl chloride (0.1 mL, 1.0 mmol, 1 equiv.) followed by the treatment with NaBH₄ in diglyme (3.4 mL, 0.6 M, 2.1


mmol, 2.1 equiv) gave methylphenyl (2-trifluoromethylphenyl)phosphine borane. (0.23 g, 88%) ^{31}P NMR (CDCl_3 , 121 MHz): $\delta = 18.5$. (lit¹⁸ 18.7)



(±)-Methyl(1-naphthyl)phenylphosphine borane: From (±)-methyl(1-naphthyl)phenylphosphine oxide (0.26 g, 1.0 mmol, 1 equiv) treated with oxalyl chloride (0.1 mL, 1.0 mmol, 1 equiv.) followed by the treatment with NaBH_4 in diglyme (3.4 mL, 0.6 M, 2.1 mmol, 2.1 equiv) gave methyl(1-naphthyl)phenylphosphine borane. (0.24 g, 91%) ^1H NMR (CDCl_3 , 300 MHz): $\delta = 8.22$ (d, $J = 8.4$ Hz, 1H, Ar), 8.00 (d, $J = 8.4$ Hz, 1H, Ar), 7.91-7.37 (m, 10H, Ar), 2.23 (d, $^2J_{\text{PH}} = 10.2$ Hz, 3H, CH_3) 1.53- 0.62 (br, m, 3H) ppm. ^{31}P NMR (CDCl_3 , 121 MHz): $\delta = 13.3$ ppm (Lit.¹⁷ 14.4 ppm).




(±)-(2,4-Dimethylphenyl)methylphenylphosphine borane : From (±)-2,4-dimethylphenyl)methylphenylphosphine oxide (0.26 g, 1.0 mmol, 1 equiv) treated with oxalyl chloride (0.1 mL, 1.0 mmol, 1 equiv.) followed by the treatment with NaBH_4 in diglyme (3.4 mL, 0.6 M, 2.1 mmol, 2.1 equiv) gave (±)-2,4-dimethylphenyl)methylphenylphosphine borane. (0.24 g, 92%) ^1H NMR (CDCl_3 , 300 MHz): $\delta = 7.64$ -7.09 (m, 8H, Ar), 2.55 (s, 3H, ArCH_3), 2.33 (s, 3H, ArCH_3), 1.99 (d, $^2J_{\text{PH}} = 9.8$ Hz, 3H, PCH_3) 0.62-1.67 (b, m, 3H, BH_3) ppm. ^{31}P NMR (CDCl_3 , 121 MHz): $\delta = 10.5$ ppm. ^{13}C NMR $\{^1\text{H}, ^{31}\text{P}\}$ (CDCl_3 , 151 MHz): $\delta = 142.8, 140.6, 138.7, 134.6, 132.6, 133.3, 131.4, 130.7, 128.4, 126.9, 21.3, 21.3, 12.8$ ppm. ^{11}B NMR (128 MHz, CDCl_3) $\delta = -36.5$ ppm) IR (KBr, cm^{-1}) ν : 3120, 2385 (BH_3), 1626, 1583, 1438, 1320, 1236, 1145, 725. HRMS ($\text{M} - \text{BH}_3 + \text{H}$)⁺ $\text{C}_{15}\text{H}_{18}\text{P}$ Calculated: 229.1146 Found: 229.1138; HPLC (CHIRALPAK[®] ASH column, 98:2 heptane: EtOH, 1 mL/min) R_t : 8.0 min, 10.2 min.




(±)-(4-Fluoro-2-methylphenyl)methylphenylphosphine borane: (±)-(4-fluoro-2-methylphenyl)methylphenylphosphine oxide (0.26 g, 1.0 mmol, 1 equiv) treated with oxalyl chloride (0.1 mL, 1.0 mmol, 1 equiv.) followed by the treatment with NaBH_4 in diglyme (3.4 mL, 0.6

M, 2.1 mmol, 2.1 equiv) gave (±)-(4-fluoro-2-methylphenyl)methylphenylphosphine borane. (0.22 g, 84%) ^1H NMR (CDCl_3 , 300 MHz): $\delta = 7.74\text{-}6.89$ (m, 8H, Ar), 2.18 (s, 3H, ArCH₃), 1.84 (d, $^2J_{\text{PH}} = 9.9$ Hz, 3H, CH₃), 0.90-1.57 (br, m, 3H, BH₃) ppm. ^{31}P NMR (CDCl_3 , 121 MHz): $\delta = 10.2$ ppm. ^{13}C NMR { ^1H , ^{31}P } (CDCl_3 , 151 MHz): $\delta = 163.11$ (d, $^1J_{\text{PF}} = 249.3$ Hz), 145.3, 137.7, 134.8, 131.2, 129.1, 127.9, 125.3, 118.4, 112.9, 21.7, 12.6 ppm. ^{11}B NMR (128 MHz, CDCl_3) $\delta = -35.7$ ppm. IR (KBr, cm^{-1}) ν : 3020, 2345 (BH₃), 1650, 1493, 1332, 1294, 1121, 1012, 742. HRMS ($\text{M} - \text{BH}_3 + \text{H}$)⁺ C₁₄H₁₅PF Calculated: 233.0895 Found: 233.0887 HPLC (CHIRALPAK[®] ASH column, 98:2 heptane: EtOH, 1 mL/min) R_t: 9.0 min, 11.0 min.




(±)-Methylphenyl(mesityl)phosphine borane: From (±)-methylphenyl(mesityl)phosphine oxide (0.26 g, 1.0 mmol, 1 equiv) treated with oxalyl chloride (0.1 mL, 1.0 mmol, 1 equiv.) followed by the treatment with NaBH₄ in diglyme (3.4 mL, 0.6 M, 2.1 mmol, 2.1 equiv) gave (±)-methylphenyl(mesityl)phosphine borane. (0.21 g, 84%)


^1H NMR (CDCl_3 , 300 MHz): $\delta = 7.49\text{-}7.42$ (m, 2H, Ar), 7.36-7.08 (m, 3H, Ar), 6.84-6.78 (m, 2H, Ar), 2.23 (s, 6H, *o*-Me), 2.20 (s, 3H, *p*-Me), 1.86 (d, $^2J_{\text{PH}} = 9.6$ Hz, 3H, PCH₃); 1.38-0.82 (b, m, 3H, BH₃) ppm. ^{31}P NMR (CDCl_3 , 121 MHz): $\delta = 11.6$ ppm. ^{13}C NMR { ^1H , ^{31}P } (CDCl_3 , 151 MHz): $\delta = 142.5$, 140.0, 134.4, 133.6, 129.9, 129.4, 129.1, 127.7, 127.1, 124.2, 22.9, 19.8, 16.0 ppm. ^{11}B NMR (128 MHz, CDCl_3) $\delta = -32.5$ ppm); IR (KBr, cm^{-1}) ν : 3010, 2356(BH₃), 1746, 1623, 1336, 1320, 1136, 765.




(±)-Cyclohexylmethylphenylphosphine borane: From (±)-(2-Cyclohexylmethylphenyl)phosphine oxide (0.23 g, 1.0 mmol, 1 equiv) treated with oxalyl chloride (0.1 mL, 1.0 mmol, 1 equiv.) followed by the treatment with NaBH₄ in diglyme (3.4 mL, 0.6 M, 2.1 mmol, 2.1 equiv) gave (±)-cyclohexylmethylphenylphosphine borane. (0.20 g, 90%) ^1H NMR (CDCl_3 , 300 MHz): $\delta = 7.73\text{-}7.46$ (m, 4H, Ar) 1.68 (d, $^2J_{\text{PH}} = 10.4$ Hz, 3H, PCH₃), 1.69-1.16 (m, 11H, *c*-Hexyl); 1.46-0.38 (br, m, 3H) ppm ^{31}P NMR (CDCl_3 , 300 MHz): $\delta = 17.1$ ppm (Lit.¹⁷ 16.2 ppm).




(±)-tert-Butylmethylphenylphosphine borane: From (±)-tert-Butylmethylphenylphosphine oxide (0.20 g, 1.0 mmol, 1 equiv) treated with oxalyl chloride (0.1 mL, 1.0 mmol, 1 equiv.) followed by the treatment with NaBH₄ in diglyme (3.4 mL, 0.6 M, 2.1 mmol, 2.1 equiv) gave (±)-tert-Butylmethylphenylphosphine borane. (0.17 g, 89%) ¹H NMR (CDCl₃, 300 MHz): δ = 7.68-7.38 (m, 5H, Ar), 1.45 (d, *J*_{HP} = 10.2 Hz, 3H), 1.09(d, *J*_{HP} = 16.5 Hz, 9H), 1.12-0.88 (br, m, 3H) ppm. ³¹P NMR (CDCl₃, 121 MHz): δ = 25.8 (lit.¹⁹ 25.3) ppm.




Tri-n-butylphosphine borane : From tri-n-butylphosphine oxide (0.21 g, 1.0 mmol, 1 equiv) treated with oxalyl chloride (0.1 mL, 1.0 mmol, 1 equiv.) followed by the treatment with NaBH₄ in diglyme (3.4 mL, 0.6 M, 2.1 mmol, 2.1 equiv) gave tri-n-butylphosphine borane. (0.19 g, 86%) ¹H NMR (CDCl₃, 300 MHz): δ = 1.55-1.47 (m, 6H), 1.45-1.32 (m, 12H), 0.85 (t, *J*_{HP} = 7.5 Hz, 9H), 0.55-0.15(br, m, 3H) ppm. ³¹P NMR (CDCl₃, 121 MHz): δ = 14.1 (lit.²⁰ 14.7) ppm.



Phenyl(o-tolyl)phosphine borane : From methylphenyl(o-tolyl)phosphine oxide (0.15 g, 1.0 mmol, 1 equiv) treated with oxalyl chloride (0.1 mL, 1.0 mmol, 1 equiv.) followed by the treatment with NaBH₄ in diglyme (3.4 mL, 0.6 M, 2.1 mmol, 2.1 equiv) gave phenyl(o-tolyl)phosphine borane. (0.13 g, 87%) ¹H NMR (CDCl₃, 300 MHz): δ = 7.82-7.30 (m, 9H, Ar), 6.58 (d, *J*_{HP} = 385 Hz, 1H), 2.46(s, 3H), 1.65-0.45 (br, m, 3H) ppm. ³¹P NMR (CDCl₃, 121 MHz): δ = -6.3 (lit.²¹ -3.8) ppm



Methylphenylphosphine borane: From Methylphenylphosphine oxide (0.14 g, 1.0 mmol, 1 equiv) treated with oxalyl chloride (0.1 mL, 1.0 mmol, 1 equiv.) followed by the treatment with NaBH₄ in diglyme (3.4 mL, 0.6 M, 2.1 mmol, 2.1 equiv) gave methylphenylphosphine borane. (0.12 g, 86%) ¹H NMR (CDCl₃, 300 MHz): δ = 7.75-7.44 (m, 9H, Ar), 5.35 (d, *J*_{HP} = 375 Hz, 1H), 1.67 (d, ²*J*_{PH} = 12.1 Hz, 3H), 0.68-0.45 (br, m, 3H) ppm. ³¹P NMR (CDCl₃, 121 MHz): δ = -13.5 (lit.²² -14.6).



(±)-*tert*-Butylphenylphosphine borane: From *tert*-butylphenylphosphine oxide (0.18 g, 1.0 mmol, 1 equiv) treated with oxalyl chloride (0.1 mL, 1.0 mmol, 1 equiv.) followed by the treatment with NaBH₄ in diglyme (3.4 mL, 0.6 M, 2.1 mmol, 2.1 equiv) gave *tert*-butylphenylphosphine borane. (0.16 g, 88%) ¹H NMR


(CDCl₃, 300 MHz): δ 7.80 -7.45 (m, 5H, Ph), 5.25 (q, *J*_{HP} = 375 Hz, 1H), 1.21 (d, *J*_{HP} = 15.2 Hz, *t*-Bu, 9H) 1.58-0.32 (m, 3H, BH₃). ³¹P NMR (CDCl₃, 121 MHz): δ =31.0 (lit¹⁹ 32.0) ppm.

(±)-*tert*-Butylphenylphosphine borane: From *tert*-butylphenylphosphine sulfide (0.20 g, 1.0 mmol, 1 equiv) treated with oxalyl chloride (0.1 mL, 1.0 mmol, 1 equiv.) followed by the treatment with NaBH₄ in diglyme (3.4 mL, 0.6 M, 2.1 mmol, 2.1 equiv) gave *tert*-butylphenylphosphine borane. (0.15 g, 86%) ³¹P NMR (CDCl₃, 121 MHz): δ =31.4 (lit¹⁹ 31.9) ppm.

Reduction of Enantioenriched phosphine oxide

Using electrophilic chlorides (*S*)-methylphenyl-*o*-tolylphosphine oxide of 93% ee was subject to the general procedure for reduction with oxalyl chloride and sodium borohydride described above. The results are shown in Table 1.

Table C Reduction of enantiomerically enriched phosphine oxide with electrophilic chlorides under various conditions.




Entry ^a	Electrophilic Chlorides	solvent	PB % ee ^b
1	(COCl) ₂	Neat	0
2	(COCl) ₂	Toluene	0
3	(COCl) ₂	DME ^d	0
4 ^c	(COCl) ₂	Toluene	0
5	(COCl) ₂	DCM	0
6	(COCl) ₂	IL ^e	0
7	SO ₂ Cl ₂	Toluene	0
8	MeSO ₂ Cl ₂	Toluene	0
9	SOCl ₂	DCM	0
10	(COCl) ₂	diethylether	0

^a = Both steps in the reaction was done at -78 °C for entries 2-10, r.t. for entry 1.; CPS (by ³¹P NMR) was same for entries 1-9; for entry 10 CPS was observed at -31 and 71 ppm which found to be covalent and ionic form respectively.²³ ^b = (PB) phosphine borane; % ee was determined by CSP HPLC; yield > 95% except for entry 8 which was 65% (by ³¹P NMR). ^c = Very slow addition of both oxalyl chloride and NaBH₄; ^d = DME: dimethoxy ethane ^e = (IL) Ionic liquid (1-methyl-3-octylimidazolium tetrafluoroborate);








General Procedure for the Stereospecific Conversion of Enantioenriched Phosphine oxide to phosphine borane

To a stirred solution of alkylating agent (1.2 mmol) in DCM or DME (2 mL) phosphine oxide (1.0 mmol) dissolved in DCM or DME (2 mL) was added dropwise at room temperature under a nitrogen atmosphere. The reaction mixture was refluxed gently for 2 hrs at which point ^{31}P NMR showed the complete conversion of phosphine oxide to the alkoxyphosphonium salt. After cooling to room temperature, sodium borohydride (3 mmol) dissolved in diglyme (5 mL) was added dropwise to the reaction mixture. This mixture was refluxed gently for 2 h. Once the ^{31}P NMR showed the full conversion of salt to phosphine borane the reaction mixture was washed with deionised water (5 mL), and the isolated organic layer was dried over anhydrous MgSO_4 . The drying agent was removed by filtration, and the solvent was removed *in vacuo* to give colourless oil, which was eluted through a silica plug using 50:50 cyclohexane/ethylacetate as eluting solvent. Solvent removal *in vacuo* yielded the pure phosphine borane.

Table D. Stereospecific reduction/boronation^a of enantioenriched phosphine oxide.



Entry	Phosphine oxide	Alkyl. agent	Yield (%) ^b	% ee ^c (config)
1 ^{d,e}	 93% ee (S)	MeOTf	62	93 (S)
2 ^e	 93% ee (S)	MeOTf	73	93 (S)
3 ^f	 93% ee (S)	$[\text{Et}_3\text{O}]\text{BF}_4$	76	93 (S)

4	 93% ee (<i>S</i>)	[Me ₃ O]BF ₄	71	93 (<i>S</i>)
5. ^g	 95% ee (<i>R</i>)	[Et ₃ O]BF ₄	67	95 (<i>R</i>)
6. ^h	 95% ee (<i>R</i>)	[Me ₃ O]BF ₄	71	95 (<i>R</i>)
7. ⁱ	 81% ee (<i>S</i>)	[Et ₃ O]BF ₄	68	81 (<i>S</i>)
8. ^j	 44 % ee	[Et ₃ O]BF ₄	67	44 ^k
9. ^l	 53 % ee (<i>R</i>)	[Et ₃ O]BF ₄	63	53 (<i>R</i>)
10.	 46 % ee (<i>S</i>)	[Et ₃ O]BF ₄	68	46 (<i>S</i>)

^a Unless otherwise specified the addition of alkylating agent (in DCM) and NaBH₄ (in diglyme) was carried at room temperature followed by refluxing; ^b isolated yield; ^c by CSP HPLC, configuration determined as described below; ^d NaBH₄ was added at -78 °C; ^e in DME solvent, methoxyphosphonium salt was observed at δ 75.9 ppm in ³¹P NMR; ^f ethoxyphosphonium salt was observed at δ 71.9 ppm in ³¹P NMR; ^g ethoxyphosphonium salt was observed at δ 70.3 ppm in ³¹P NMR; ^h methoxyphosphonium salt was observed at δ 73.8 ppm in ³¹P NMR; ⁱ ethoxyphosphonium salt was observed at δ 67.8 ppm in ³¹P NMR; ^j ethoxyphosphonium salt was observed at δ 78.3 ppm in ³¹P NMR; ^k % ee of phosphine oxide, obtained by converting scalemic phosphine borane to scalemic phosphine oxide using DABCO and H₂O₂; config remains to be assigned; ^l ethoxyphosphonium salt was observed at δ 89.8 ppm in ³¹P NMR.

Table D

Entry 1: (*S*)-Methylphenyl(*o*-tolyl)phosphine oxide (0.23 g, 1.0 mmol, 1 equiv) was treated with methyl triflate (0.13 mL, 1.2 mmol, 1.2 equiv.) in DME solvent followed by the treatment with NaBH₄ in diglyme (6 mL, 0.5 M, 3.0 mmol, 3.0 equiv) gave methylphenyl(*o*-tolyl)phosphine borane (0.14 g, 62%, 93 % ee (*S*))

Entry 2: (*S*)-Methylphenyl(*o*-tolyl)phosphine oxide (0.23 g, 1.0 mmol, 1 equiv) was treated with methyl triflate (0.13 mL, 1.2 mmol, 1.2 equiv.) in DME solvent followed by the treatment with NaBH₄ in diglyme (6 mL, 0.5 M, 3.0 mmol, 3.0 equiv) gave (*S*)-methylphenyl(*o*-tolyl)phosphine borane (0.16 g, 73%, 93 % ee (*S*))

Entry 3: (*S*)-Methylphenyl(*o*-tolyl)phosphine oxide (0.23 g, 1.0 mmol, 1.0 equiv) was treated with (triethyloxonium tetrafluoroborate) [Et₃O]BF₄ (0.22 g, 1.2 mmol, 1.2 equiv.) in DCM solvent followed by the treatment with NaBH₄ in diglyme (6 mL, 0.5 M, 3.0 mmol, 3.0 equiv) gave methylphenyl(*o*-tolyl)phosphine borane (0.17 g, 76%; 93 % ee (*S*))

Entry 4: (*S*)-Methylphenyl(*o*-tolyl)phosphine oxide (0.23 g, 1.0 mmol, 1.0 equiv) was treated with (trimethyloxonium tetrafluoroborate) [Me₃O]BF₄ (0.17 g, 1.2 mmol, 1.2 equiv.) in DCM solvent followed by the treatment with NaBH₄ in diglyme (6 mL, 0.5 M, 3.0 mmol, 3.0 equiv) gave methylphenyl(*o*-tolyl)phosphine borane (0.16 g, 71%; 93 % ee (*S*))

Entry 5: (*R*)-Methylphenyl(anisyl)phosphine oxide (0.25 g, 1.0 mmol, 1.0 equiv) was treated with (triethyloxonium tetrafluoroborate) [Et₃O]BF₄ (0.22 g, 1.2 mmol, 1.2 equiv.) in DCM solvent followed by the treatment with NaBH₄ in diglyme (6 mL, 0.5 M, 3.0 mmol, 3.0 equiv) gave methylphenyl(anisyl)phosphine borane (0.16 g, 67%; 95 % ee (*R*))

Entry 6: (*R*)-Methylphenyl(anisyl)phosphine oxide (0.25 g, 1.0 mmol, 1 equiv) was treated with (trimethyloxonium tetrafluoroborate) [Me₃O]BF₄ (0.17 g, 1.2 mmol, 1.2 equiv.) in DCM solvent followed by the treatment with NaBH₄ in diglyme (6 mL, 0.5 M, 3.0 mmol, 3.0 equiv) gave methylphenyl(anisyl)phosphine borane (0.17 g, 71%; 95 % ee (*R*))

Entry 7: (*S*)-Methylphenyl(biphenyl)phosphine oxide (0.14 g, 0.5 mmol, 1 equiv) was treated with (triethyloxonium tetrafluoroborate) [Et₃O]BF₄ (0.11 g, 0.6 mmol, 1.2 equiv.) in DCM solvent followed by the treatment with NaBH₄ in diglyme (3 mL, 0.5 M, 1.5 mmol, 3.0 equiv) gave methylphenyl(biphenyl)phosphine borane (95 mg, 68%; 81 % ee (*S*))

Entry 8: (*R*)-Methylphenyl(mesityl)phosphine oxide (85 mg, 0.3 mmol, 1 equiv) was treated with (triethyloxonium tetrafluoroborate) [Et₃O]BF₄ (73 mg, 0.4 mmol, 1.2 equiv.) in DCM solvent followed by the treatment with NaBH₄ in diglyme (2 mL, 0.5 M, 1.0 mmol, 3.0 equiv) gave methylphenyl(mesityl)phosphine borane (52 mg, 67%). For HPLC analysis methylphenyl(mesityl)phosphine borane was treated with DABCO (1.2 equiv) followed by hydrogen peroxide (1.2 equiv) to give (*S*)-Methylphenyl(mesityl)phosphine oxide 44 % ee.





Entry 9: (*R*)- *tert*-Butylmethylphenylphosphine oxide (0.19 g, 1.0 mmol, 1 equiv) was treated with (triethyloxonium tetrafluoroborate) [Et₃O]BF₄ (0.22 g, 1.2 mmol, 1.2 equiv.) in DCM solvent followed by the treatment with NaBH₄ in diglyme (6 mL, 0.5 M, 3.0 mmol, 3.0 equiv) gave *tert*-Butylmethylphenylphosphine borane (0.12 g, 63%; 53 % ee (*R*))






Entry 10: (*S*)- *tert*-Butylmethylphenylphosphine oxide (0.19 g, 1.0 mmol, 1 equiv) was treated with (triethyloxonium tetrafluoroborate) [Et₃O]BF₄ (0.22 g, 1.2 mmol, 1.2 equiv.) in DCM solvent followed by the treatment with NaBH₄ in diglyme (6 mL, 0.5 M, 3.0 mmol, 3.0 equiv) gave *tert*-Butylmethylphenylphosphine borane (0.13 g, 68%; 46 % ee (*S*))

Determination of absolute configurations of phosphine oxide and borane



These were assigned according to the literature reported data. Thus 93% (*S*)-methylphenyl-*o*-tolyl phosphine oxide and 95 % (*R*)-methylphenylanisylphosphine oxide obtained from Celtic Catalysts Ltd. was confirmed as the (*S*) and (*R*) enantiomer respectively by HPLC comparison with the phosphine oxide obtained from an asymmetric Appel reaction on racemic methylphenyl-*o*-tolylphosphine with (+)-menthol and HCA, which gave (*S*)-enantiomer of phosphine oxide,²⁴ reaction on racemic methylphenylanisylphosphine with (-)-menthol and HCA, which gave (*R*)-enantiomer of phosphine oxide.²⁵

The Absolute configuration of phosphine oxide and phosphine borane were assigned by comparison with the literature reported (cited near the entry no.) HPLC data.



Entry	Phosphine oxide and Phosphine borane	Column	Condition	t1 (min)	t2 (min)
1. ²⁴		Chiralpak IA	Heptane/Et-OH = 80/20 1 mL/min	7.4 (<i>S</i>)	8.4 (<i>R</i>)
2. ¹³		Chiralpak AS-H	Heptane/Et-OH = 98/02 1 mL/min	10.1 (<i>R</i>)	12.5 (<i>S</i>)
3. ²⁵		Chiralpak IA	Heptane/Et-OH = 90/10 1 mL/min	14.6(<i>R</i>)	15.9(<i>S</i>)
4. ¹⁴		Chiralpak AS-H	Heptane/Et-OH = 98/02 1 mL/min	12.3(<i>R</i>)	13.1(<i>S</i>)



5. ²⁵		Chiralpak AS-H	Heptane/Et-OH = 90/10 1 mL/min	8.1 (<i>R</i>)	10.2 (<i>S</i>)
6. ²⁵		Chiralpak AS-H	Heptane/Et-OH = 98/02 1 mL/min	11.6 (<i>R</i>)	13.1 (<i>S</i>)
7. ²⁶		Chiralpak IA	Heptane/Et-OH = 90/10 1 mL/min	8.9	10.3
8. ²⁷		Chiralpak IA	Heptane/Et-OH = 90/10 1 mL/min	8.0 (<i>S</i>)	10.2 (<i>R</i>)
9. ²⁷		Chiralpak OJH	Heptane/Et-OH = 70/30 1 mL/min	9.0 (<i>S</i>)	10.2 (<i>R</i>)

NMR spectra and HPLC traces of phosphine boranes.




PHOSPHORUS_001
TPP_BH3










PROTON_001
Otol-bh3-OL





PHOSPHORUS_001
ot_










PHOSPHORUS_001
PAMP_BH3







PHOSPHORUS_001
P+DIPAMP-OTOL




PROTON_001
otol-dipamp-Bh3







PHOSPHORUS_001
otoI-dipamp-Bh3





PHOSPHORUS_001
P+BINAP











PHOSPHORUS_001
dibenzophosphole-borane







PHOSPHORUS_001
ortho-ph-bh3










PHOSPHORUS_001
IPA-BH3




PHOSPHORUS_001
OC_P+_Isopropyl












#


















PHOSPHORUS_001
PFTMP_borane_full











































PHOSPHORUS 001







Supporting HPLC Traces

Entry 2 in Table A


Racemic methylphenyl-*o*-tolylphosphine oxide

```
=====
Acq. Operator   : General sequence           Seq. Line :    4
Acq. Instrument : Kev HPLC 1                Location  : Vial 2
Injection Date  : 3/13/2010 6:22:51 PM      Inj       :    1
                                           Inj Volume: 5 µl

Acq. Method     : C:\Chem32\1\DATA\AOB4-3-10 2010-03-13 17-07-41\ISO_80_20_30MIN_1MLMIN.M
Last changed    : 3/13/2010 6:22:39 PM by General sequence
                  (modified after loading)

Analysis Method : C:\CHEM32\1\DATA\AOB4-3-10 2010-03-13 17-07-41\002-0401.D\DA.M (ISO_80_20_
                  30MIN_1MLMIN.M)

Last changed    : 7/8/2009 9:49:45 AM by General sequence
Method Info     : Isocratic at 80/20 heptane/EtOH for 30min at 1ml/min
=====
```



```
=====
Area Percent Report
=====
```

```
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Use Multiplier & Dilution Factor with ISTDs
```


Signal 1: DAD1 D, Sig=230,8 Ref=360,100

Entry 1-4 in Table D

Scalemic methylphenyl-*o*-tolylphosphine oxide used as starting material

```
=====
Acq. Operator   : General sequence           Seq. Line :    5
Acq. Instrument : Kev HPLC 1                Location  : Vial 3
Injection Date  : 3/13/2010 7:04:04 PM      Inj       :    1
                                           Inj Volume: 5 µl

Acq. Method    : C:\Chem32\1\DATA\AOB4-3-10 2010-03-13 17-07-41\ISO_80_20_30MIN_1MLMIN.M
Last changed   : 3/13/2010 7:03:52 PM by General sequence
                (modified after loading)
Analysis Method: C:\CHEM32\1\DATA\AOB4-3-10 2010-03-13 17-07-41\003-0501.D\DA.M (ISO_80_20_
                30MIN_1MLMIN.M)
Last changed   : 3/15/2010 10:58:35 AM by General sequence
Method Info    : Isocratic at 80/20 heptane/EtOH for 30min at 1ml/min
=====
```



Area Percent Report

```
Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1 D, Sig=230,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.321	BV	0.2061	2.74307e4	2103.87964	96.3471
2	8.363	VB	0.1894	1040.00745	83.42152	3.6529


Entry 2 in Table A

Racemic methylphenyl-*o*-tolylphosphine phosphine borane

=====
Instrument Conditions : At Start At Stop
Column Temp. (left) : 24.9 24.9 °C
Column Temp. (right) : 26.0 26.0 °C
Pressure : 54.1 54.5 bar
Flow : 1.000 1.000 ml/min
Valve 1 Position : 4 4

Detector Lamp Burn Times: Current On-Time Accumulated On-Time
DAD 1, UV Lamp : 1.75 1193.6 h
DAD 1, Visible Lamp : OFF 11.2 h


Solvent Description :
PMP1 , Solvent A : Heptane
PMP1 , Solvent B : EtOH



Entry 1 and 2 in Table D

Scalemic methylphenyl*o*-tolylphosphine borane obtained by using MeOTf as alkylating agent and NaBH₄ as reductant

```
=====
Acq. Operator   : General sequence           Seq. Line :    5
Acq. Instrument : Kev HPLC 1                Location  : Vial 11
Injection Date  : 1/27/2010 5:27:07 PM      Inj       :    1
                                           Inj Volume: 5 µl
Acq. Method     : C:\Chem32\1\DATA\RUN QUEUE 2010-01-27 16-52-30\ISO_98_02_60MIN_1MLMIN.M
Last changed    : 1/27/2010 5:26:56 PM by General sequence
                  (modified after loading)
Analysis Method : C:\CHEM32\1\METHODS\03_QUICKSTART 1 MLMIN METHODS\ISO_98_02_30MIN_1MLMIN.M
Last changed    : 6/28/2010 8:54:49 PM by General sequence
Method Info     : Isocratic at 98/02 heptane/EtOH for 30min at 1ml/min
=====
```



Area Percent Report

```
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Use Multiplier & Dilution Factor with ISTDs
```


Signal 1: DAD1 D, Sig=230,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.519	MM	0.1778	40.71126	3.81536	3.4379
2	12.328	MM	0.2483	1143.46362	76.75564	96.5621

Entry 3 in Table D

Salemic methylphenyl-*o*-tolylphosphine borane obtained by using $[\text{Et}_3\text{O}]^+\text{BF}_4^-$ as alkylating agent and NaBH_4 as reductant

```
=====
Acq. Operator   : General sequence           Seq. Line :   11
Acq. Instrument : Kev HPLC 1                Location  : Vial 12
Injection Date  : 1/30/2010 4:22:14 PM      Inj       :    1
                                           Inj Volume: 5 µl
Acq. Method     : C:\Chem32\1\DATA\RUN QUEUE 2010-01-30 13-49-46\ISO_98_02_45MIN_1MLMIN.M
Last changed    : 1/30/2010 4:22:04 PM by General sequence
                 (modified after loading)
Analysis Method : C:\CHEM32\1\METHODS\03_QUICKSTART 1 MLMIN METHODS\ISO_98_02_30MIN_1MLMIN.M
Last changed    : 6/28/2010 8:54:49 PM by General sequence
Method Info     : Isocratic at 98/02 heptane/EtOH for 30min at 1ml/min
=====
```



Area Percent Report

```
Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1 D, Sig=230,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.372	MM	0.1752	77.54230	7.37590	3.3947
2	12.187	MM	0.2471	2206.69824	148.81880	96.6053


Entry 4 in Table D

Salemic methylphenyl-*o*-tolylphosphine borane obtained by using $\text{Me}_3\text{O}^+\text{BF}_4$ as alkylating agent and NaBH_4 as reductant

```
=====
Acq. Operator   : General sequence           Seq. Line :    7
Acq. Instrument : Kev HPLC 1                Location  : Vial 41
Injection Date  : 7/31/2010 10:11:53 PM     Inj       :    1
                                           Inj Volume: 5 µl

Acq. Method    : C:\Chem32\1\DATA\RUN QUEUE 2010-07-31 19-14-37\ISO_98_02_30MIN_1MLMIN.M
Last changed   : 7/31/2010 10:11:43 PM by General sequence
                (modified after loading)

Analysis Method: C:\CHEM32\1\METHODS\03_QUICKSTART 1 MLMIN METHODS\ISO_98_02_30MIN_1MLMIN.M
Last changed   : 6/28/2010 8:54:49 PM by General sequence
Method Info    : Isocratic at 98/02 heptane/EtOH for 30min at 1ml/min
=====
```



Area Percent Report

```
Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1 D, Sig=230,8 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.915	MM	0.2885	890.90057	51.46819	3.2664
2	12.229	MM	0.3290	2.63839e4	1336.55017	96.7336

Entry 3 in Table A

Racemic (±)anisylmethylphenylphosphine oxide

```
=====
Acq. Operator   : DGG                               Seq. Line :    7
Acq. Instrument : HPLC1                             Location  : Vial 91
Injection Date  : 9/10/2011 7:34:12 PM              Inj       :    1
                                                    Inj Volume: 5.000 µl
Acq. Method     : C:\CHEM32\1\DATA\AA GENERAL SEQUENCE 2011-08-10 18-06-36\ISO_90_10_30MIN_
                  IMLMIN.M
Last changed    : 9/23/2010 3:52:29 PM by General sequence
Analysis Method : C:\CHEM32\1\METHODS\03_QUICKSTART 1 IMLMIN METHODS\ISO_90_20_15MIN_1MLMIN.M
Last changed    : 9/4/2011 6:16:04 PM by DGG
                  (modified after loading)
Method Info     : Isocratic at 80/20 heptane/EtOH for 15min at 1ml/min
=====
```

Additional Info : Peak(s) manually integrated



Area Percent Report

```
Sorted By      :      Signal
Multiplier:    :      1.0000
Dilution:      :      1.0000
Use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1.D, Sig=230.8 Ref=360.100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	14.687	BB	0.3342	1909.66724	86.95485	50.3049
2	15.928	BB	0.3617	1896.52759	79.84065	49.6952

Totals : 3796.19482 166.79550


*** End of Report ***

Entry 5-6 in Table D

Scalemic anisylmethylphenylphosphine oxide 95.7 % ee (R)

```
-----  
Acq. Operator   : DGG                               Seq. Line :    8  
Acq. Instrument : HPLC1                             Location  : Vial 02  
Injection Date  : 8/10/2011 8:08:12 PM              Inj       :    1  
                                                    Inj Volume: 5.000 µl  
Acq. Method     : C:\CHEM32\1\DATA\AA GENERAL SEQUENCE 2011-08-10 18-06-36\ISO_00_10_30MIN_1MLMIN.M  
Last changed    : 8/28/2010 3:52:29 PM by General sequence  
Analysis Method : C:\CHEM32\1\METHODS\10_FLOW 0,5 MLMIN METHODS\ISO_00_01_15MIN_0_5MLMIN.M  
Last changed    : 8/7/2011 12:36:50 PM by DGG  
                (modified after loading)  
Method Info     : Isocratic at 00/01 heptane/EtOH for 15min at 0.5ml/min
```

Additional Info : Peak(s) manually integrated



Area Percent Report

```
-----  
Sorted By      :      Signal  
Multiplier:    :      1.0000  
Dilution:      :      1.0000  
Use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1 C, Sig=210,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	14.405	VV	0.4367	9.93322e4	2051.40723	97.8821
2	15.006	VB	0.3938	2149.28979	82.53716	2.1179

Totals : 1.01481e5 3033.94438


*** End of Report ***

Entry 3 in Table A

Racemic (\pm)anisylmethylphenylphosphine borane

```
=====
Acq. Operator   : General sequence           Seq. Line :    3
Acq. Instrument : Kev HPLC 1                Location  : Vial 11
Injection Date  : 6/29/2010 10:17:16 PM     Inj       :    1
                                           Inj Volume: 5 µl

Acq. Method     : C:\Chem32\1\DATA\RUN QUEUE 2010-06-29 21-42-34\ISO_98_02_30MIN_1MLMIN.M
Last changed    : 6/29/2010 10:17:05 PM by General sequence
Analysis Method : C:\CHEM32\1\METHODS\01_COLUMN METHODS\STABILISE_98_02_10MIN_1MLMIN.M
Last changed    : 6/29/2010 9:32:43 PM by General sequence
Method Info     : Stabilise column at 99/1 heptane/EtOH for 10min at 1ml/min
=====
```



=====
Area Percent Report
=====

```
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1 D, Sig=230,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	12.366	BV	0.2707	2.86744e4	1650.24219	49.7663
2	13.135	VV	0.3028	2.89437e4	1502.02356	50.2337


Entry 5 and 6 in Table D

Scalemic anisylmethylphenylphosphine borane 95.6 % ee

```
=====
Acq. Operator   : DGG                               Seq. Line :    3
Acq. Instrument : HPLC1                             Location  : Vial 22
Injection Date  : 9/10/2011 2:00:49 PM              Inj       :    1
                                                    Inj Volume: 5.000 µl

Acq. Method    : C:\CHEM32\1\DATA\AA GENERAL SEQUENCE 2011-09-10 13-47-15\ISO_99_02_30MIN_
                1MLMIN.M
Last changed   : 2/25/2011 9:47:10 AM by KV
Analysis Method: C:\CHEM32\1\METHODS\10_FLOW 0,5 MLMIN METHODS\ISO_99_01_15MIN_0_5MLMIN.M
Last changed   : 9/7/2011 12:36:50 PM by DGG
                (modified after loading)
Method Info    : Isocratic at 99/01 heptane/EtOH for 15min at 0.5ml/min
=====
```

Additional Info : Peak(s) manually integrated



Area Percent Report

```
Sorted By      :      Signal
Multiplier:    :      1.0000
Dilution:      :      1.0000
Use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1 D, Sig=230,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	15.755	MM	0.3171	8158.71533	428.82748	97.7888
2	16.720	MM	0.4489	184.48784	6.84908	2.2112

Totals : 8343.20317 435.67657


*** End of Report ***

Entry 7 in Table D

Scalemic (2-Biphenyl)methylphenylphosphine oxide 81 % ee (5)

```
=====
Acq. Operator   : DGG                               Seq. Line :    3
Acq. Instrument : HPLC1                             Location  : Vial 13
Injection Date  : 9/10/2011 11:30:59 AM             Inj       :    1
                                                    Inj Volume: 5.000 µl
Acq. Method    : C:\CHEM32\1\DATA\AA GENERAL SEQUENCE 2011-09-10 11-17-26\ISO_90_20_30MIN_
                1MLMIN.M
Last changed   : 4/1/2011 10:02:37 AM by K
Analysis Method: C:\CHEM32\1\METHODS\10_FLOW 0,5 MLMIN METHODS\ISO_99_01_15MIN_0_5MLMIN.M
Last changed   : 9/7/2011 12:36:50 PM by DGG
                (modified after loading)
Method Info    : Isocratic at 99/01 heptane/EtOH for 15min at 0.5ml/min
=====
```

Additional Info : Peak(s) manually integrated



Area Percent Report

```
Sorted By      :      Signal
Multiplier:    :      1.0000
Dilution:      :      1.0000
Use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1 A, Sig=254,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.170	MM	0.2664	439.40555	27.42945	9.4239
2	10.290	MM	0.3307	4213.71143	212.37991	90.5762
Totals :				4652.11697	239.80936	


*** End of Report ***

Entry 8 in Table A

Racemic (\pm)-(2-Biphenyl)methylphenylphosphine borane

```
=====
Acq. Operator   : General sequence           Seq. Line :    6
Acq. Instrument : Kev HPLC 1                 Location  : Vial 2
Injection Date  : 6/2/2010 10:34:56 PM      Inj       :    1
                                           Inj Volume: 5 µl

Acq. Method     : C:\Chem32\1\DATA\RUN QUEUE 2010-04-21 18-10-30\RUN QUEUE 2010-06-02 20-48-
45\ISO_98_02_30MIN_1MLMIN.M
Last changed    : 6/2/2010 10:34:46 PM by General sequence
                 (modified after loading)
Analysis Method : C:\CHEM32\1\METHODS\03_QUICKSTART 1 MLMIN METHODS\ISO_98_02_30MIN_1MLMIN.M
Last changed    : 5/20/2010 11:50:38 AM by General sequence
Method Info     : Isocratic at 98/02 heptane/EtOH for 30min at 1ml/min
=====
```



Area Percent Report

```
Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1 D, Sig=230,8 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.746	VB	0.2174	3.00823e4	2148.21655	49.6276
2	10.063	BB	0.2695	3.05337e4	1767.96008	50.3724

Entry 7 in Table D

Scalemic (2-Biphenyl)methylphenylphosphine borane 81 % ee(S)

```
=====
Acq. Operator   : DGG                               Seq. Line :    5
Acq. Instrument : HPLC1                             Location  : Vial 12
Injection Date  : 9/10/2011 12:12:29 PM             Inj       :    1
                                                    Inj Volume: 5.000 µl
Acq. Method     : C:\CHEM32\1\DATA\AA GENERAL SEQUENCE 2011-09-10 11-17-26\ISO_99_02_30MIN_
IMLMIN.M
Last changed    : 2/25/2011 9:47:10 AM by KV
Analysis Method : C:\CHEM32\1\METHODS\10_FLOW 0,5 MLMIN METHODS\ISO_99_01_15MIN_0_5MLMIN.M
Last changed    : 9/7/2011 12:36:50 PM by DGG
                (modified after loading)
Method Info     : Isocratic at 99/01 heptane/EtOH for 15min at 0.5ml/min
=====
```

Additional Info : Peak(s) manually integrated



Area Percent Report

```
Sorted By      :      Signal
Multiplier:    :      1.0000
Dilution:      :      1.0000
Use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1 D, Sig=230,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.625	BV	0.2372	3552.69263	231.29472	9.5416
2	13.121	VV	0.3252	3.36810e4	1589.36267	90.4584
Totals :				3.72337e4	1820.65739	

*** End of Report ***

Entry 14 in Table A


Racemic methylphenyl(mesityl)phosphine oxide

Acq. Operator : Seq. Line : 28
Acq. Instrument : Kev HPLC 1 Location : Vial 73
Injection Date : 9/14/2011 5:45:55 PM Inj : 1
Inj Volume : 5 µl
Acq. Method : C:\Chem32\1\DATA\DGG\RUN QUEUE 2011-09-14 08-46-12\ISO_90_10_30MIN_1MLMIN.M
Last changed : 9/14/2011 5:45:44 PM
(modified after loading)
Analysis Method : C:\CHEM32\1\METHODS\14_OTHER METHODS\GARY\RI 98_2_30MIN_1MLMIN.M
Last changed : 9/14/2011 1:45:45 PM
(modified after loading)
Method Info : 98/02 for 30 min at 1ml/min
RI detector on

Instrument Conditions : At Start At Stop
Column Temp. (left) : 24.0 23.9 °C
Column Temp. (right) : 25.2 25.1 °C
Pressure : 50.9 51.3 bar
Flow : 1.000 1.000 ml/min
Valve 1 Position : 1 1

Detector Lamp Burn Times: Current On-Time Accumulated On-Time
DAD 1, UV Lamp : 9.01 3126.3 h
DAD 1, Visible Lamp : OFF 97.5 h

Solvent Description :
FMP1, Solvent A : Heptane
FMP1, Solvent B : EtOH



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	15.561	MM	0.3886	1.52327e4	653.39349	54.2340
2	17.194	MM	0.4407	1.28543e4	496.17926	45.7660

Totals : 2.80870e4 1139.57275


Entry 8 in Table D

Scalemic methylphenyl(mesityl)phosphine oxide 44 % ee (R)

Valve 1 Position : 1 1

Detector Lamp Burn Times: Current On-Time Accumulated On-Time
DAD 1, UV Lamp : 15.51 3116.3 h
DAD 1, Visible Lamp : OFF 87.5 h

Solvent Description :
PMP1, Solvent A : Heptane
PMP1, Solvent B : EtOH



Signal 1: DAD1 0, Sig=230,8 Res=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	15.536	MX	0.4578	5.44125e4	1981.13857	72.5803
2	17.307	MX	0.4830	2.03552e4	739.92208	27.4197

Totals : 7.49888e4 2721.06073


Entry 8 in Table D

Scalemic methylphenyl(mesityl)phosphine oxide 44 % ee (S)

Instrument Conditions : At Start At Stop
Column Temp. (left) : 23.5 23.5 °C
Column Temp. (right) : 24.5 24.5 °C
Pressure : 45.5 52.1 bar
Flow : 1.000 1.000 ml/min
Valve 1 Position : 1 1

Detector Lamp Burn Times: Current On-Time Accumulated On-Time
DAD 1, UV Lamp : 16.04 3116.8 h
DAD 1, Visible Lamp : OFF 87.3 h

Solvent Description :
PMF1, Solvent A : Heptane
PMF1, Solvent B : EtOH



Signal 1: DAD1.D, Sig=230.8 Ref=360.100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	15.591	PK	0.3806	1.32555e4	668.03705	27.3083
2	17.146	PK	0.4912	4.02051e4	1364.27258	72.4917

Totals : 5.34616e4 2032.30963

Entry 16 in Table A

Racemic -*tert*-Butylmethylphenylphosphine oxide


Instrument Conditions	:	At Start	At Stop
Column Temp. (left)	:	29.3	29.4 °C
Column Temp. (right)	:	29.3	29.4 °C
Pressure	:	70.1	71.1 bar
Flow	:	1.000	1.000 ml/min
Valve 1 Position	:	5	5

Detector Lamp Burn Times:	Current On-Time	Accumulated On-Time
DAD 1, UV Lamp	: 4.88	1156.3 h
DAD 1, Visible Lamp	: OFF	11.2 h

Solvent Description :

FMP1, Solvent A : Heptane

FMP1, Solvent B : EtOH



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.017	VB	0.1921	1.09237e4	923.13629	49.4947
2	10.219	BB	0.2665	1.16019e4	661.75677	51.5053


Totals : 2.25255e4 1594.89307

Entry 9 in Table D

Scalemic (*R*)-*tert*-Butylmethylphenylphosphine oxide 53 % ee

Detector Lamp Burn Times: Current On-Time Accumulated On-Time
DAD 1, UV Lamp : 3.66 1155.1 h
DAD 1, Visible Lamp : OFF 11.2 h

Solvent Description :
PMF1, Solvent A : Heptane
PMF1, Solvent B : EtOH



Signal 1: DAD1 D, Sig=230,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	12.379	BV	0.4211	5409.17627	199.34335	23.2056
2	14.111	VB	0.6644	1.79007e4	399.26746	76.7944


Totals : 2.33099e4 596.61081

Entry 10 in Table D

Scalemic (*S*)-*tert*-Butylmethylphenylphosphine oxide 46 % ee

Acq. Operator : DGG
Acq. Instrument : HPLC1
Injection Date : 9/9/2011 9:32:41 PM
Seq. Line : 3
Location : Vial 2
Inj : 1
Inj Volume : 5.000 µl
Acq. Method : C:\CHEM32\1\DATA\AA GENERAL SEQUENCE 2011-09-09 21-19-08\ISO_90_10_30MIN_1MLMIN.M
Last changed : 9/25/2010 3:52:29 PM by General sequence
Analysis Method : C:\CHEM32\1\METHODS\10_FLOW 0,5 MLMIN METHODS\ISO_99_01_15MIN_0_5MLMIN.M
Last changed : 9/7/2011 12:36:50 PM by DGG
(modified after loading)
Method Info : Isocratic at 99/01 heptane/EtOH for 15min at 0.5ml/min

Additional Info : Peak(s) manually integrated



Area Percent Report

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.401	MM	0.2253	6078.11670	449.64005	73.0401
2	9.212	MM	0.2347	2243.49780	159.30034	26.9599
Totals :				8321.61450	608.94038	

*** End of Report ***

Entry 16 in Table A


Racemic -*tert*-Butylmethylphenylphosphine borane

Instrument Conditions	:	At Start	At Stop
Column Temp. (left)	:	29.3	29.4 °C
Column Temp. (right)	:	29.3	29.4 °C
Pressure	:	70.1	71.1 bar
Flow	:	1.000	1.000 ml/min
Valve 1 Position	:	5	5

Detector Lamp Burn Times:	Current On-Time	Accumulated On-Time
DAD 1, UV Lamp	: 4.88	1156.3 h
DAD 1, Visible Lamp	: OFF	11.2 h

Solvent Description :

FMP1, Solvent A	: Heptane
FMP1, Solvent B	: EtOH



Signal 1: DAD1.D, Sig=230,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.017	VB	0.1821	1.09237e4	923.13629	48.4947
2	10.219	BB	0.2665	1.16019e4	661.75677	51.5053

Totals : 2.25255e4 1584.89307


Entry 9 in Table D

Scalemic (*R*)-*tert*-Butylmethylphenylphosphine borane 53 % ee

Instrument Conditions : At Start At Stop
Column Temp. (left) : 29.2 29.2 °C
Column Temp. (right) : 30.6 30.7 °C
Pressure : 72.5 76.8 bar
Flow : 1.000 1.000 ml/min
Valve 1 Position : 4 4

Detector Lamp Burn Times: Current On-Time Accumulated On-Time
DAD 1, UV Lamp : 1.41 1101.8 h
DAD 1, Visible Lamp : OFF 11.2 h

Solvent Description :
FMP1, Solvent A : Heptane
FMP1, Solvent B : EtOH



Signal 1: DAD1 A, Sig=254,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.164	MM	0.2163	5651.20459	435.51163	23.4236
2	10.557	MM	0.2992	1.84749e4	1028.95654	76.5764

Totals : 2.41261e4 1464.46817

Entry 10 in Table D


Scalemic (*S*)-*tert*-Butylmethylphenylphosphine borane 46 % ee

```
-----  
Acq. Operator   :                               Seq. Line : 21  
Acq. Instrument : Nav HPLC 1                     Location  : Vial 31  
Injection Date  : 9/13/2011 5:34:20 PM           Inj       : 1  
                                                    Inj Volume: 5 µl  
Acq. Method    : C:\Chem32\1\DATA\DSG\RUN QUEUE 2011-09-13 10:58-41\150_70_30MIN_1MLMIN.M  
Last changed   : 9/13/2011 5:34:09 PM           (modified after loading)  
Analysis Method: C:\CHEM32\1\METHODS\14_OTHER METHODS\GARY\RI 98_2_30MIN_1MLMIN.M  
Last changed   : 9/14/2011 10:48:10 PM           (modified after loading)  
Method Info    : 98/02 for 30 min at 1ml/min  
                RI detector on  
-----
```

```
-----  
Instrument Conditions : At Start      At Stop  
Column Temp. (left)  : 24.0          24.1 °C  
Column Temp. (right) : 25.1          25.2 °C  
Pressure             : 58.1          73.8 bar  
Flow                 : 1.000          1.000 ml/min  
Valve 1 Position     : 2            2  
-----
```

```
Detector Lamp Run Times: Current On-Time Accumulated On-Time  
DAD 1, UV Lamp         : 5.60          3107.4 h  
DAD 1, Visible Lamp    : OFF            87.5 h  
-----
```

```
Solvent Description :  
PMP1, Solvent A     : Heptane  
PMP1, Solvent B     : EtOH  
-----
```



```
Sorted By      : Signal  
Multiplier     : 1.0000  
Dilution       : 1.0000  
Use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1 D, Sig=230,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.367	XX	0.2521	5906.56689	390.52283	73.2867
2	13.972	XX	0.3639	2152.96362	98.60745	26.7133

Totals : 8059.53052 489.13028

Entry 9 in Table A


Racemic (\pm)-methylphenyl(2-*i*-propylphenyl)phosphine borane

```
=====
Acq. Operator   : General sequence           Seq. Line :    3
Acq. Instrument : Kev HPLC 1                 Location  : Vial 16
Injection Date  : 12/9/2010 10:41:45 AM      Inj       :    1
                                           Inj Volume: 5 µl

Acq. Method     : C:\Chem32\1\DATA\RUN QUEUE 2010-12-09 10-08-43\ISO_99_01_30MIN_1MLMIN.M
Last changed    : 12/9/2010 10:41:34 AM by General sequence
                 (modified after loading)

Analysis Method : C:\CHEM32\1\METHODS\01_COLUMN METHODS\SELECT IA COLUMN.M
Last changed    : 11/30/2010 9:11:53 AM by General sequence
                 (modified after loading)

Method Info     : Select IA column
=====
```



=====
Area Percent Report
=====

```
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Use Multiplier & Dilution Factor with ISTDs
```


Signal 1: DAD1 D, Sig=230,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.995	BB	0.3106	1399.54749	68.43586	49.9362
2	11.376	BV	0.4867	1403.12354	44.63789	50.0638

Entry 1 in Table B

Racemic (\pm)methyl(*o*-tolyl)phosphine borane

```
=====
Acq. Operator   : General sequence           Seq. Line : 11
Acq. Instrument : Kev HPLC 1                Location  : Vial 5
Injection Date  : 4/3/2010 8:07:36 PM       Inj       : 1
                                           Inj Volume: 5 µl
Acq. Method     : C:\Chem32\1\DATA\RUN QUEUE 2010-04-03 14-55-48\ISO_97_03_30MIN_1MLMIN.M
Last changed    : 4/3/2010 5:22:21 PM by General sequence
Analysis Method : C:\CHEM32\1\DATA\RUN QUEUE 2010-04-03 14-55-48\005-1101.D\DA.M (ISO_97_03_30MIN_1MLMIN.M)
Last changed    : 3/22/2010 9:23:07 AM by General sequence
Method Info     : Isocratic at 97/03 heptane/EtOH for 30min at 1ml/min
=====
```



```
=====
Area Percent Report
=====
```

```
Sorted By      : Signal
Multiplier     : 1.0000
Dilution      : 1.0000
Use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1 D, Sig=230,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.231	BB	0.2433	8590.73535	540.99377	50.5975
2	12.857	VB	0.2840	8387.83105	457.26364	49.4025


Entry 15 in Table A

Racemic(±)-Cyclohexymethylphenylphosphine borane

```
=====
Acq. Operator   : General sequence                Seq. Line :    3
Acq. Instrument : Kev HPLC 1                     Location  : Vial 11
Injection Date  : 12/19/2009 12:54:02 PM         Inj       :    1
                                                    Inj Volume: 5 µl

Acq. Method     : C:\Chem32\1\DATA\RUN QUEUE 2009-12-19 12-39-51\ISO_96_04_15MIN_1MLMIN.M
Last changed    : 12/19/2009 12:53:52 PM by General sequence
                  (modified after loading)
Analysis Method : C:\CHEM32\1\DATA\RUN QUEUE 2009-12-19 12-39-51\011-0301.D\DA.M (ISO_96_04_
                  15MIN_1MLMIN.M)
Last changed    : 12/19/2009 3:45:55 PM by General sequence
Method Info     : Isocratic at 95/04 heptane/EtOH for 15min at 1ml/min

Sample Info     : ASH 96 4 pen ethan
=====
```



=====
Area Percent Report
=====

```
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1 D, Sig=230,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.966	BV	0.1268	1.20409e4	1451.20239	49.6250
2	7.851	VV	0.1819	1.22229e4	1049.30774	50.3750

Entry 13 in Table A


Racemic(\pm)-(4-Fluoro-2-methylphenyl)methylphenylphosphine borane

```
=====
Acq. Operator   : General sequence           Seq. Line :    4
Acq. Instrument : Kev HPLC 1                Location  : Vial 12
Injection Date  : 6/27/2010 7:23:21 PM      Inj       :    1
                                           Inj Volume: 5 µl

Acq. Method     : C:\Chem32\1\DATA\RUN QUEUE 2010-06-27 18-09-05\ISO_98_02_30MIN_1MLMIN.M
Last changed    : 6/27/2010 7:23:09 PM by General sequence
                 (modified after loading)

Analysis Method : C:\CHEM32\1\METHODS\03_QUICKSTART 1 MLMIN METHODS\ISO_98_02_30MIN_1MLMIN.M
Last changed    : 6/23/2010 10:22:59 AM by General sequence
                 (modified after loading)

Method Info     : Isocratic at 98/02 heptane/EtOH for 30min at 1ml/min
=====
```



Area Percent Report

```
Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1 D, Sig=230,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.057	VB	0.2060	2.55190e4	1933.06165	49.0175
2	11.005	VBA	0.2663	2.65420e4	1545.97217	50.9825

Entry 12 in Table A

Racemic(±)-(4-methyl-2-methylphenyl)methylphenylphosphine borane

```
=====
Acq. Operator   : General sequence           Seq. Line : 12
Acq. Instrument : Kev HPLC 1                Location  : Vial 13
Injection Date  : 7/21/2010 4:03:40 PM      Inj       : 1
                                           Inj Volume: 5 µl

Acq. Method     : C:\Chem32\1\DATA\RUN QUEUE 2010-07-21 11-21-13\ISO_70_30_30MIN_1MLMIN.M
Last changed    : 7/21/2010 4:03:30 PM by General sequence
                 (modified after loading)


Analysis Method : C:\CHEM32\1\METHODS\01_COLUMN METHODS\STABILISE_98_02_10MIN_1MLMIN.M
Last changed    : 7/5/2010 9:52:01 AM by General sequence
                 (modified after loading)

Method Info     : Stabilise column at 99/1 heptane/EtOH for 10min at 1ml/min
=====
```

```
Instrument Conditions : At Start           At Stop
Column Temp. (left)  : 28.3                28.4 °C
Column Temp. (right) : 29.3                29.4 °C
Pressure              : 70.1                71.1 bar
Flow                  : 1.000              1.000 ml/min
Valve 1 Position     : 5                  5
```

```
Detector Lamp Burn Times: Current On-Time Accumulated On-Time
DAD 1, UV Lamp         : 4.88             1156.3 h
DAD 1, Visible Lamp    : OFF              11.2 h
```

```
Solvent Description :
PMP1 , Solvent A    : Heptane
PMP1 , Solvent B    : EtOH
```



Entry 11 in Table A


Racemic(±)-(±)-methyl-(1-naphthyl)phenylphosphine borane

```
=====
Acq. Operator   : General sequence           Seq. Line :    4
Acq. Instrument : Kev HPLC 1                Location  : Vial 11
Injection Date  : 2/15/2010 10:40:38 PM     Inj       :    1
                                           Inj Volume: 5 µl

Acq. Method     : C:\Chem32\1\DATA\RUN QUEUE 2010-02-15 21-45-18\ISO_98_02_45MIN_1MLMIN.M
Last changed    : 2/15/2010 10:40:28 PM by General sequence
                 (modified after loading)

Analysis Method  : C:\CHEM32\1\DATA\RUN QUEUE 2010-02-15 21-45-18\011-0401.D\DA.M (ISO_98_02_
                 45MIN_1MLMIN.M)

Last changed    : 2/16/2010 10:09:50 AM by General sequence
Method Info     : Isocratic at 98/02 heptane/EtOH for 45min at 1ml/min
=====
```



=====
Area Percent Report
=====

```
Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1 D, Sig=230,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.343	VB	0.2055	2.14471e4	1630.19421	49.8742
2	11.251	BB	0.2462	2.15553e4	1365.22644	50.1258

References

1. L. M. Harwood, C. J. Moody, J. M. Percy, *Experimental Organic Chemistry* 2nd ed. **1999**, Blackwell Science Ltd. Oxford.
2. Bergin, E.; O'Connor, C. T.; Robinson, S. B.; McGarrigle, E. M.; O'Mahony, C. P.; Gilheany, D. G., *J. Am. Chem. Soc.* **2007**, *129*, 9566-9567
3. Rajendran, K. V.; Kennedy, L.; Gilheany, D. G., *Eur. J. Org. Chem.* **2010**, 5642-5649.
4. Korpiun, O.; Lewis, R. A.; Chickos, J.; Mislow, K. J. *J. Am. Chem. Soc.* **1968**, *90*, 4842-4846;
5. Dalton, C. T.; Ryan, K. M.; Langan, I. J.; Coyne, É. J.; Gilheany, D. G., *J. Mol. Catal. A: (Chem.)* **2002**, *187*, 179-187.
6. Imamoto, T.; Sato, K.; Johnson, C. R. *Tetrahedron Lett.* **1985**, *26*, 783-786.
7. Blank, N. F.; Moncarz, J. R.; Brunker, T. J.; Scriban, C.; Anderson, B. J.; Amir, O.; Glueck, D. S.; Zakharov, L. N.; Golen, J. A.; Incarvito, C.D.; Rheingold, A. L.; *J. Am. Chem. Soc.* **2007**, *129*, 6847-6858.
8. Xu, Q.; Zhao, C.-Q.; Han, L.-B., *J. Am. Chem. Soc.* **2008**, *130*, 12648-12655.
9. Stankiewicz, M.; Nycz, J.; Rachon, J., *Heteroatom Chem.* **2002**, *13*, 330-339.
10. Corey, E. J.; Chen, Z.; Tanoury, G. J., *J. Am. Chem. Soc.* **1993**, *115*, 11000-11001;
11. Perlikowska, W.; Gouygou, M.; Daran, J.-C.; G. B.; Mikołajczyk, M., *Tetrahedron Lett.* **2001** *42*, 7841-7845.
12. Overschelde, M. V.; Vervecken, E.; Modha, S. G.; Cogen, S.; Eycken, E. V. D.; Eycken, J. V. D., *Tetrahedron* **2009**, *65*, 6410-6415.
13. Wada, Y.; Imamoto, T.; Tsuruta, H.; Yamaguchi, K.; Gridnev, I. D., *Adv. Synth. Catal.* **2004**, *346*, 777-788;
14. Kaloun, E. B.; Merdés, R.; Genet, J.-P.; Uziel, J.; Jugé, S., *J. Organomet. Chem.* **1997**, *529*, 455-463.
15. (a) Juge, S.; Stephan, M.; Laffitte, J. A.; Genet, J. P. *Tetrahedron Lett.* **1990**, *31*, 6357-6300;
(b) McKinstry, L.; Livinghouse, T. *Tetrahedron Lett.* **1994**, *35*, 9319-9322.
16. (a). Shimada, T.; Kurushima, H.; Cho, Y.-H.; Hayashi, T., *J. Org. Chem.* **2001**, *66*, 8854-8858;
(b). Imamoto, T.; Kikuchi, S.; Miura, T.; Wada, Y., *Org. Lett.* **2000**, *3*, 87-90.
17. Bauduin, C.; Moulin, D.; Kaloun, E. B.; Darcel, C.; Juge, S., *J. Org. Chem.* **2003**, *68*, 4293-4301.
18. Al-Masum, M.; Kumaraswamy, G.; Livinghouse, T., *J. Org. Chem.* **2000**, *65*, 4776-4778.

19. Stankevic, M. ; Pietrusiewicz, K. M., *Tetrahedron Lett.* **2009**, *50*, 7093-7095.
20. Busacca, C. A.; Raju, R.; Grinberg, N.; Haddad, N.; James-Jones, P.; Lee, H.; Lorenz, J. C.; Saha, A.; Senanayake, C. H., *J. Org. Chem.* **2008**, *73* 1524-1531
21. Stankevic, M.;Pietrusiewicz, K. M., *Synlett* **2003**, 1012-1016.
22. Lebel, H.; Morin,S.; Paquet, V., *Org. Lett.* **2003**, *5*, 2347-2349.
23. (a) Godfrey, S. M.; McAuliffe, C. A.; Pritchard, R. G.; Sheffield, J. M., *Chem. Commun.* **1996**, 2521-2522; (b) Godfrey, S. M.; McAuliffe, C. A.; Pritchard, R. G.; Sheffield, J. M., *Chem. Commun.* **1998**, 921-922; (c) Godfrey, S. M.; Hinchliffe, A.; Mkadmh, A., *J Mol Struc - Theochem* **2005**, *719*, 85-88.
24. King, G.; Bergin, E.; Muller-Bunz, H.; Gilheany, D. G., *Acta Cryst.* **2007**, *E63*, o3278.
25. King, G.; Gilheany, D. G.; Cumming, G. R. **2010**, Patent WO 2010004278 A1 20100114.
26. Configuration remains to be assigned.
27. D. Gatineau, L. Laurent Giordano, G. Buono, *J. Am. Chem. Soc.* **2011**, *133*, 10728;